US Pharma Giants Q3 Earnings: High Dividends and Innovative Drug Pipelines Resonate, Dividend Pharma Sector Seeks New Opportunities\nIn the third quarter of 2026, the US pharmaceutical ind...
Read Full Article
In the US stock market in 2026, the dividend medicine sector is demonstrating unique investment appeal. This sector combines the stability of traditional high-dividend blue-chip pharmaceutical compani...
Read Full Article
In the context of continued global capital market polarization in 2026, the US pharmaceutical dividend sector is exhibiting unique investment appeal. This sector features a "dual-wheel drive" of high-...
Read Full Article
In 2026, the global biomedical industry is undergoing a profound transformation driven by artificial intelligence. As multiple AI pharma companies list on US stock markets, this emerging field is r...
Read Full Article
Pharma Giants' AI Strategy Upgrade: Innovation and Dividends Dual-Driving US Pharma Sector Under the wave of rapid development in artificial intelligence technology, the global pharmaceuti...
Read Full Article
AI Pharma IPO Boom: New Investment Frontier in US Biotech for 2026\nSince 2026, the US biopharmaceutical market has witnessed an unprecedented wave of change. The deep integration of artif...
Read Full Article
US Medical Sector Dual Engine: High Dividend Blue Chips and Innovative Biotech Resonance Analysis\nIn 2026, the US medical market presents a unique dual-engine landscape: on one hand, trad...
Read Full Article
Against the backdrop of recent intensified volatility in the US stock market due to valuation disagreements in AI computing power, the pharmaceutical sector has once again played the dual role of "...
Read Full Article
On August 4, 2026, the U.S. pharma sector received major news: Merck & Co., Inc. (NYSE: MRK) announced that MK-8891, its AI-discovered lung cancer candidate, had been granted Breakthrough Therapy d...
Read Full Article
As the US stock market seeks both offense and defense, the combination of dividends and healthcare is becoming a safe haven for capital. On August 3, healthcare giant Johns...
Read Full Article
